Welcome Dear Sir/Madam,

Thank you for your interest in our special conference dedicated to “Securing a Flexible Future” for pharmaceutical manufacturing. As you will likely know, pharmaceutical companies around the world are under tremendous pressure to reduce drug costs; regulators, legislators, payers, and patients are all demanding that action be taken. To that end, pharmaceutical company leaders are keen to maximize any potential cost savings – especially when planning for the launch of a new product. In our discussions with pharmaceutical industry leaders, it has become clear that regardless of company size, product type, or market, the challenge of demand forecasting for new product launches is significant. Developed to inform manufacturing commitments, demand forecasts come into play as many as 4–5 years before product launch; naturally, variables and market conditions change in the intervening time – so those forecasts are often wrong! And yet, these ‘uncertain’ forecasts are used by manufacturing and supply chain executives to make decisions about building new facilities or purchasing manufacturing capacity. Contractual relationships with CMOs are also driven by forecasts – especially critical elements like pricing, capacity availability, as well as financial agreements, such as take-or-pay contracts. Is this course of action sustainable? We believe change is long overdue, and so we look forward to welcoming you at Hotel Euler, Basel, Switzerland, on 26 April 2017. To reserve your free place, complete this short registration form.

Yours faithfully,

Patheon & The Medicine Maker Collaborating on “Securing a Flexible Future”

SECURINGA FLEXIBLE

FUTURE

Coffee and Welcome

Welcome from The Medicine Maker – Rich Whitworth

Dr Daniel MekicPresentation title: “Great Expectations: The Outsourced Pharmaceutical Manufacturing Sector”. Rich Whitworth Presentation title: “Impact Of Incorrect Forecasts On New Product Launches”. Spotlight on the results of research conducted by ORC International, which included in-depth interviews with 50 pharma industry executives with experience implementing demand forecasts for commercial launches.

Networking Lunch

Joe Principe Presentation title: “Nothing Is Set in Stone: Why a Buy-or-Build Model Doesn’t Always Meet Real-World Requirements”.In an ever-evolving industry, traditional business models may no longer meet the basic needs for a go-to-market strategy, which explains why pharma companies often require a new set of “must-haves”. Here, Joe Principe considers the increasing need for flexibility in uncertain times. Panel Discussion: ‘Turning Manufacturing Challenges Into Opportunities’.

Agenda

09:00 – 09:45

09:45 – 10:00

10:00 – 11:00

11:00 – 12:00

12:00 – 13:00

13:00 – 14:00

14:00 – 15:00

SECURINGA FLEXIBLE

FUTURE

SECURINGA FLEXIBLE

FUTURE

Speaker Bios Rich Whitworth Content Director, Texere Publishing Rich Whitworth completed his studies in medical biochemistry at the University of Leicester, UK, in 1998. To cut a long story short, he eventually escaped to Tokyo, where he spent five years working for the largest English-language publisher in Japan. Carving out a career in Tokyo apparently changed his outlook forever – “When seeing life through such a kaleidoscopic lens, it’s hard not to get truly caught up in the moment,” he says. On returning to the UK, Rich combined his love of science with a passion for quality content, and worked in the pharmaceutical manufacturing and sustainable investment spaces before being invited into the colorful folds of Texere Publishing. Having spearheaded the editorial development of The Analytical Scientist, Rich became Content Director and is now responsible for maintaining high editorial quality across all publications, including The Medicine Maker. Joe Principe Vice President of Strategic Partnerships, Patheon Pharmaceuticals

Joe is currently Vice President of Strategic Partnerships at Patheon Pharmaceuticals. He has over 18 years experience in the CDMO industry. Previous to Patheon, Joe has worked within the Pharmaceutical services industry with Abbott Laboratories (ABBVIE), Evonik Degussa and Piramal Healthcare. Joe holds B.S. a in Chemistry and Biology from Loyola University, Chicago and an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University majoring in Marketing, Management and Strategy. Joe has also served as an Executive Officer of DCAT (Drug Chemical and Associated Technologies Association) and is a past president.

Dr Daniel Mekic Results Healthcare‘s Associate Principal

Daniel is an Associate Principal in the Healthcare team with transactions experience in licensing, divestments and venture capital investments. Daniel previously worked at Merck KGaA, where he was a Director in the Biosimilar business development team, executing transactions to build and support the newly established business unit. This included scouting, due diligence and execution of transactions. Prior to this role, he was a Senior Financial Controller for Merck’s licensing team, where he was responsible for asset and strategy evaluations.